BEIJING – Despite tensions between the U.S. and China, especially in the tech sector, Oncologie Inc. maintains its plans to pursue drug development in both markets. The clinical-stage startup, led by U.S. scientists and funded with Chinese capital, has stationed itself in both Boston and Shanghai to focus on developing innovative cancer therapies simultaneously in China and the U.S.

BEIJING – Chinese startup Biotheus Inc., of Zhuhai, Guangdong, has its sights fixed on bispecific and multitarget antibodies to maximize drug efficacy. A biotech innovator based in the south of China, it is gained support from local authorities that aim to create another biotech hub in the country.

BEIJING – Chinese startup Biotheus Inc., of Zhuhai, Guangdong, has its sights fixed on bispecific and multitarget antibodies to maximize drug efficacy. A biotech innovator based in the south of China, it gained support from local authorities that aim to create another biotech hub in the country.

HONG KONG – Singaporean biotech company Aum Biosciences Pte. Ltd. has in-licensed a potentially first-in-class PIM/PI3K/mTOR inhibitor from Inflection Biosciences Ltd., of Dublin and London, to develop it globally to treat a wide range of cancers.

HONG KONG –Biocure Technology Corp., a Canadian biopharmaceutical company focusing on biosimilar products, is advancing a CAR T product through its South Korean subsidiary, Biocurepharm Inc., thanks to a recently closed private placement.

LONDON - Oncolytic virus startup Theolytics Ltd. is looking to raise a series A round as it prepares to take its first product into phase I in the treatment of multiple myeloma.

TEL AVIV, Israel – With shares now listed in the U.S. and data from a pivotal trial for its key bladder cancer therapy coming soon, Anchiano Therapeutics Ltd. is poised to ride the wave of interest in gene therapy.

Phagomed Biopharma GmbH, a Viennese company born of frustrations with the rise of multidrug-resistant infections and confidence in the potential for bacteriophage therapies to address them, has landed a €1.5 million (US$1.7 million) equity investment from new and existing investors. It's the second part of a €2.3 million seed financing, raised ahead of a series A round the company hopes to secure in 2020 to help it move toward the clinic in 2021.

Century Therapeutics Inc. came out of stealth mode Monday with $250 million in funding commitments from lead investor Bayer AG, founding investor Versant Ventures and strategic partner Fujifilm Holdings Corp. to develop next-generation allogeneic cell therapies for cancer, based on induced pluripotent stem cells (iPSCs).

PERTH, Australia – After a AU$2 million (US$1.4 million) capital raise in April, Perth-headquartered Pharmaust Ltd. will advance its lead compound monepantel into phase I trials in humans.